Abstract
Knowledge about the safe and effective use of medicines in neonates has increased substantially but has resulted in few label changes. Drugs developed for use in adults are reshaped and tailored to specific neonatal indications. However, the use of drugs in neonates should not only mirror adult pharmacotherapy, but should be driven by their own specific needs. Therefore, building collaborative networks may assist to develop a newborn-driven research agenda addressing their clinical needs and diseases.
© 2015 American Society for Clinical Pharmacology and Therapeutics.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Age Factors
-
Animals
-
Chemistry, Pharmaceutical
-
Child Development
-
Dose-Response Relationship, Drug
-
Drug Dosage Calculations
-
Drug-Related Side Effects and Adverse Reactions / etiology
-
Drug-Related Side Effects and Adverse Reactions / prevention & control
-
Humans
-
Infant, Newborn
-
Infant, Newborn, Diseases / diagnosis
-
Infant, Newborn, Diseases / drug therapy*
-
Infant, Newborn, Diseases / metabolism
-
Pharmaceutical Preparations / administration & dosage*
-
Pharmaceutical Preparations / chemistry
-
Pharmaceutical Preparations / metabolism
-
Pharmacogenetics
-
Pharmacokinetics
-
Risk Assessment
-
Risk Factors
Substances
-
Pharmaceutical Preparations